Platform Optimization for Efficient AAV Purification

Over the last decade, the number of clinical trials involving recombinant adeno-associated viral (AAV) vectors has dramatically increased, the diversity of serotypes has expanded and the demand for larger quantities of highly purified material manufactured to cGMP standards has rocketed.

Download this whitepaper to discover how a contract development and manufacturing organization was able to:

• Establish an AAV production platform
• Implement one single chromatography media to purify various AAV stereotypes